Hypofractionated radiotherapy schedules for carcinoma of the cervix have been evaluated previously but have been associated with an increased incidence of acute gastrointestinal toxicity. The HOPE trial tests whether a dose‑painting approach—delivering differential doses to the primary tumour and elective nodal clinical target volumes—can permit safe hypofractionation in patients at low risk of pelvic nodal relapse. By limiting dose to elective nodal volumes in selected node‑negative patients, the investigators aim to reduce acute GI adverse events while maintaining oncologic efficacy.
The study population is restricted to patients with Human Papillomavirus (HPV)‑associated squamous cell carcinoma of the cervix without pelvic nodal involvement on PET‑CT and MRI, reflecting the subgroup with low nodal relapse risk for whom elective nodal dose de‑escalation may be clinically justified.
HOPE is a phase II, multi‑center, open‑label, randomized, parallel‑group, superiority study. Participants are randomly allocated to one of two external beam radiotherapy regimens given with concurrent weekly cisplatin.
Control arm (conventional radiotherapy, CRT): Whole‑pelvic radiotherapy delivering 45 Gy in 25 fractions (1.8 Gy per fraction) to both the primary clinical target volume (CTVp) and the nodal clinical target volume (CTVn). Concurrent cisplatin is administered at 40 mg/m2 weekly for five cycles.
Experimental arm (hypofractionated dose‑painted radiotherapy, HDRT): A dose‑painted schedule in 20 fractions delivering 42.5 Gy (2.125 Gy per fraction) to the CTVp and 36 Gy (1.8 Gy per fraction) to the CTVn. Concurrent cisplatin is given at 50 mg/m2 weekly for four cycles.
The open‑label design means treating clinicians and patients are aware of allocation. Radiotherapy target definitions, planning, and delivery details are described in the protocol; supplementary materials are available with the preprint.
Key inclusion criteria reported in the protocol are:
Further eligibility details (such as performance status, prior treatments, or organ function thresholds) are part of the full protocol; if not reported in the preprint, those specifics were not provided in the source.
Primary outcome:
Secondary outcomes include:
The primary statistical analysis will be performed on the intention‑to‑treat population. The primary outcome will be analyzed with a covariate‑adjusted log binomial model to estimate the relative risk of grade ≥2 acute GI toxicity between arms.
The protocol assumes an absolute reduction in the rate of grade ≥2 acute GI toxicity from 35% in the control arm to 21% in the HDRT arm (14% absolute risk reduction). Using an asymmetric two‑sided group sequential design with three planned interim analyses and targeting 80% power at a 5% one‑sided type I error, the required sample size is 274 patients.
Interim analyses are planned as part of the group sequential design; precise stopping boundaries and detailed statistical monitoring plans are provided in the trial protocol. The primary outcome will be reported with covariate adjustment per the stated model.
Ethics review and approvals: The trial will begin at participating centres after institutional review board approval at each site. The Ethics Committee of Tata Medical Centre, Kolkata provided ethical approval for this work and the authors confirm adherence to relevant ethical guidelines.
Consent and participant protections: All patients must provide written informed consent prior to enrollment. The authors state that patient/participant consent and institutional documentation have been archived and that identifying information is not available outside the research group.
Competing interests: The authors declared no competing interests in the preprint.
Trial registration: The study is prospectively registered in the Clinical Trials Registry of India under CTRI/2026/05/111292.
Data availability: The preprint states that all data produced in the study are available upon reasonable request to the authors.
Dissemination: Results are planned for presentation in peer‑reviewed journals and at academic conferences. The source is a medRxiv preprint and has not been peer reviewed; the authors and platform note that findings should not yet be used to guide clinical practice.
Notes: The preprint includes supplementary material and links to protocol resources. Specific operational details (for example, additional eligibility thresholds, radiotherapy planning constraints, and detailed quality‑of‑life instruments) are referenced in the protocol and supplementary files; if any of these were not detailed in the preprint, those specifics were not reported in the source.